Live·Open questions in longevity research
All news
Biotech fundingNeurotechnology

Science Corporation raises $400 million for a retinal implant and a brain interface made of living neurons

18 November 2026· 261118011

Science Corporation raises $400 million for a retinal implant and a brain interface made of living neurons

On November 17, Science Corporation, founded by former Neuralink president Max Hodak, announced its Series D funding round. The funding will help prepare the PRIMA implant for launch in the US, accelerate access in Europe, and increase investment in a brain interface made of living neurons. According to Bloomberg and TechCrunch, the company's valuation rose from $1,5 billion after its Series C round in March to $3,5 billion.

PRIMA is a 2 × 2 mm chip implanted beneath the retina in patients with late-stage age-related macular degeneration, in which the light-sensitive cells at the center of the retina have died. Glasses equipped with a camera transmit an infrared image to the chip, which stimulates surviving nerve cells. According to the company, patients can read letters and words again. In July, PRIMA received CE marking, allowing it to enter the European market. Bloomberg reports that two patients in Germany have received the commercial version of the chip, with dozens more operations planned.

In the US, Science is seeking FDA approval through the Humanitarian Device Exemption pathway for diseases that affect no more than 8 000 people a year. This pathway waives the usual requirements to demonstrate effectiveness: the FDA weighs probable benefit against risk. Macular degeneration is too common to qualify, so the FDA granted PRIMA Humanitarian Use Device designation for a narrowly defined group: people who have lost vision in both eyes to the disease. Hodak told Bloomberg that he expects US sales to begin in the first half of 2027.

Investors in the round include the Ackman Oxman Institute, a neuroscience and longevity institute that billionaire Bill Ackman and his wife, Neri Oxman, launched in August. At the time, Ackman wrote: “We live in a world where we can be confident that blind people will soon see again. We will do everything we can to bring that day closer, including supporting companies already working in this field.” In September, the institute became one of the lead investors in a funding round for another neurotechnology company, Precision Neuroscience.

The brain interface made of living neurons is a project led by Science co-founder Alan Mardinly. In a talk in July, he outlined the company's plan: restoring vision is a conventional, safe business through which Science develops technology for brain interfaces, then uses living cells to build the next generation of interfaces. An electrode destroys some brain tissue, so Science grows neurons from stem cells and makes them light-sensitive. The cell bodies remain inside the implant, alongside electrodes that record signals and LEDs that stimulate the cells with light; only the cells' extensions grow into the brain. Hodak wrote in 2024:

“The basic idea is fairly simple: since the brain already consists largely of neurons, what happens if you add more neurons? They grow into it and form extensive connections.”

In the same talk, Mardinly showed that human neural progenitor cells placed on the surface of a mouse's brain formed synapses with the mouse's neurons. Human neurons were also transplanted into a monkey: an LED activated neurons in the monkey's brain 2 mm from the transplant, but not 10 mm away. The company hopes to begin human trials within 16 months, Bloomberg reported. It has selected the first disease to target but has not disclosed it.

Yale neurosurgeon Murat Günel is designing these trials with the company and sees promise for treating Parkinson's disease. Today, surgeons implant an electrode that only reduces tremor. “If we can actually put [transplanted] cells back into the brain and protect these circuits, there is a chance, and I believe a good chance, that we could stop the disease from progressing.”

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#science-corporation#prima-implant#retinal-prosthesis#biohybrid-interface#series-d#macular-degeneration